“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, et al. Eur Respir J 2022; 59: 2002463. This evidence concerns the gene IL6 and pulmonary arterial hypertension.